MEK inhibitors were ineffective in overcoming endocrine resistance in breast cancer cell lines stimulated by growth factors such as fibroblast growth factor 1 (FGF-1) and heregulin β1 (HRGβ1) [115]. Here, FGF1 is linked to breast cancer.